Dichotomania in embryo claims

Embryo‑selection marketing and risk claims exploit 'dichotomania' — the habit of converting continuous traits into sharp disease/no‑disease cutoffs — to report large relative risk reductions that correspond to negligible average phenotype change. Regulators, clinicians and journalists should require vendors to report both the expected absolute phenotypic shift and the distributional mechanics (how many individuals sit near the threshold) rather than only relative risk percentages. — Standardizing how genetic‑risk reductions are framed will prevent consumer deception, inform clinical consent, and guide policy on the ethical use and advertising of polygenic embryo selection.